Pesonalised Risk Prediction For Severe Treatment-related Gastrointestinal Toxicity In Paediatric Cancer Patients Using Pre-treatment Gut Microbiome Analysis
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
The gut is home to trillions of good and bad bacteria, critical to human health. Each person has a different balance of bacteria, unique to their gut, which shapes their immune system and susceptibility to disease. I will investigate how the unique gut bacteria, in children with blood cancer, can be used to predict which children will develop severe gut side effects (diarrhoea) from their chemotherapy. This will identify high-risk children, enable personalised treatment and improve survival.
Development Of Prognostic And Predictive Biomarkers To Aid Treatment Of Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.